Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03894891 · ClinicalTrials.gov registry record · Phase 2
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03894891 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 6 participants.
The verdict
NCT03894891, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Nivolumab
- RADIATION Intensity-modulated radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03894891
The ClinicalTrials.gov registry entry for NCT03894891 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT03894891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03894891 about?
NCT03894891 is a clinical study titled "Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer". This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
What is the current status of trial NCT03894891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-06-11. Estimated completion is 2022-12-16.
What interventions are being tested in trial NCT03894891?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Nivolumab (DRUG), Intensity-modulated radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03894891?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.